Word: herceptin
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...biologics, it is expected that, with 633 biotechnology medicines in development last year for more than 100 diseases, half the new drugs approved in 2015 will be. Biologics average more than 20 times the cost of traditional drugs: treating breast cancer with a year's worth of the biologic Herceptin can cost $48,000; Remicade, for rheumatoid arthritis, can cost $20,000 annually. For other, rarer diseases, the price of biologic treatments can be as high as $200,000 a year...
Roche, however, retains one key advantage: it has already seen its own line of attack succeed. The proof? Roche's first targeted breast-cancer drug, Herceptin. Developed by Genentech, Herceptin was marketed specifically to destroy cancers containing the her-2/neu protein, which doctors can detect using a 21-gene screen diagnostic. Herceptin has helped thousands of women combat breast cancer. But there's no doubt it has also helped Roche's bottom line: at $40,000 a year per patient, Herceptin grew globally in sales nearly 25%, to $4.1 billion, last year. "You need self-confidence to take risks...
...magazine [Oct. 15]. Breast cancer is indeed becoming a global concern and strikes women regardless of age or socioeconomic level. My fiancé, who is 32, is one of the survivors. She had surgery, received chemotherapy, went bald and took medicines mentioned in your report such as tamoxifen and Herceptin. She is currently healthy and living a better life than before. Having a strong will to survive means you are on your way to being cured; we leave the rest to prayers and medicine. Alexander Abimanyu, jakarta...
...type that is partly stimulated by exposure to estrogen. This is one reason the disease usually hits in middle age, after 25 or so years of the monthly hormonal surges associated with ovulation and menstruation. Since the cancer relies on estrogen to grow, drugs like tamoxifen and Herceptin, which block hormone receptors on malignant cells, can help starve the disease...
...patients with recent diagnoses. At Duke University, molecular geneticist Joseph Nevins is testing a similar gene-based test for lung cancer. Researchers are aiming for tools that will tell them not only whether chemo is needed but also which specific drugs to use. Such a screen already exists for Herceptin, and many others are in development. Meantime, at the M.D. Anderson Cancer Center in Houston, Dr. Roy Herbst, chief of thoracic medical oncology, is looking for protein markers on lung tumors that will enable doctors to make the best choice among four different drug combinations...